CAN-FITE BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4 ILa | +5.26% |
|
+29.03% | +53.85% |
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.04
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +53.85% | 17.46M | |
| +6.96% | 101B | |
| +8.29% | 42.63B | |
| +82.32% | 29.77B | |
| -11.82% | 16.14B | |
| +1.39% | 14.31B | |
| -12.13% | 11.55B | |
| +176.65% | 10.53B | |
| +6.74% | 9.2B | |
| -55.52% | 8.98B |
- Stock Market
- Equities
- CANF Stock
- News Can-Fite BioPharma Ltd.
- Can Fite BioPharma : Aegis Capital Starts Can-Fite Biopharma at Buy with $5 Price Target
